Accellta develops, manufactures and markets a range of game-changing solutions for the cost-effective industrialization of stem cell manufacturing. Our technologies can save more than 90% of the cost and 65% of the time of pluripotent, progenitor and differentiated cells mass-manufacturing comparing to classical adherent culture systems.
This includes proprietary technologies for expanding and differentiating human Embryonic and Induced Pluripotent Stem Cells in suspension devoid of feeder cells and with no need for micro-carriers.
These technologies enable continuous, robust and reproducible expansion and induced differentiation of stem cells using dynamic bioreactors, in a cost-effective manner, offering unprecedented magnitude and quality.
The potential uses of our technologies are numerous, ranging from regenerative medicine, bio-fabrication and 3D-bioprinting to tissue- and organ-on-a-chip for drug screening.
Our technologies are the fruits of over 15 years of pioneering research and development at the Stem Cell Center in the Technion’s Rappaport Faculty of Medicine.
Accellta was established in 2012 through a seed investment from the Alfred Mann Institute of the Technion. Our last investment round was led by Horizons Ventures.
We have already established several agreements with leading companies that manufacture, market and sell stem cells culture media, based on our rich Intellectual Property.
We are offering our partners the custom-made development of up-scalable, robust manufacturing of stem cells and designated media for regenerative medicine or drug screening purposes. We also plan to develop tissues and biochips based on a range of stem cells derived functional cells for screening and testing of drug candidates, in collaboration with leaders in bio-fabrication and 3D-bioprinting industries, as well as a range of stem cell based products for selected medical and aesthetic indications.